© 2008 American Association for Clinical Chemistry
Tacrolimus, a macrolide immunosuppressant produced by the bacterium Streptomyces tsukabaensis (1 ) , is used for the prevention of organ rejection (2, 3 ) by preventing T-lymphocyte activation (4 ) . Toxicity concerns (5 ) dictate patient monitoring, and a variety of different diagnostic immunoassays are commercially available (6 ) . Tacrolimus binds to a cytosolic immunophilin protein, FK-506 binding protein (7 ) , and the complex is located in erythrocytes. Organic solvents (e.g., methanol, ethanol, methylene chloride) used for extraction from whole blood samples before measurement often lower the functional activity of the antibody used in the immunoassay, with the potential for reduced accuracy and robustness (8 ) .
The recent advent of in vitro antibody display technologies provides the flexibility to engineer new or augment specific attributes of interest, such as affinity, specificity, or stability, into previously isolated antibody molecules, a process often termed "directed evolution." A central tenet of any in vitro display platform is that the phenotype of the displayed protein must be coupled to the gene encoding the displayed protein. This coupling allows diverse libraries to be sampled and the coding sequence to be recovered from clones identified with desired properties. Yeast display (9 ) (Fig. 1A ) has proven to be a highly effective platform for various directed evolution applications, including affinity maturation (10 -12 ) and changes in specificity (13, 14 ) . Single-chain fragment variable (scFv) 2 antibodies, in which the antigen-specific immunoglobulin variable heavy (VH) and variable light (VL) domains are linked into a single polypeptide, are displayed on the yeast surface as a fusion protein to a cell wall component. Fluorescence activated cell sorting (FACS) coupled with yeast cell surface display enables monitoring of both antibody expression on the cell surface and the ability of that antibody to bind antigen (Fig. 1B ). Discrete populations differing in affinity and/or epitope specificity can be visualized, and desired clones can be quantitatively recovered (15) (16) (17) .
Improvements in the affinity of the recognition reagents used in any given immunoassay often dictate ultimate performance and utility. Tacrolimus immunoassays with improvements in the limit of quantification (LOQ) or the limit of detection (LOD) will need to be developed as more effective treatment regimens are adopted. We used in vitro directed evolution to increase the binding affinity of the tacrolimus 1-60-46 antibody in the presence of 10% methanol to determine degree of improvement with the Architect Tacrolimus immunoassay.
Materials and Methods

IDENTIFICATION OF TACROLIMUS 1-60-46 VARIABLE GENES
We extracted mRNA from tacrolimus 1-60-46 hybridoma cell line (Abbott Laboratories code 93339) using Oligotex direct mRNA isolation kit (Qiagen). We synthesized Ig cDNA using MuIgGVH3Ј-2 (5Ј-CCCA AGCTTCCAGGGRCCARKGGATARACIGRTGG-3Ј) and MuIgVL3Ј-1 (5Ј-CCCAAGCTTACTGGATG GTGGGAAGATGGA-3Ј) primers (Mouse Ig-Primer set; Novagen) with SuperScript III reverse transcriptase (Invitrogen). The Ig cDNA was PCR amplified: VH reactions from IgG cDNA used MuIgVH3Ј-2 and MuIgVH5Ј A-F primers (Mouse Ig-Primer set; Novagen) and VL reactions from Ig cDNA used MuIgVH3Ј-1 and MuIgkVH5Ј A-G primers (Mouse Ig-Primer set; Novagen). PCR reactions were ligated into pCR2.1 TOPO vector (Invitrogen), and plasmid DNA was sequenced from a number of transformants.
CONSTRUCTION OF TACROLIMUS WILD-TYPE scFV FOR YEAST
DISPLAY
We used tacrolimus VH or VL TOPO plasmid DNA to amplify the appropriate gene with gene-specific 5Ј and 3Ј primers. VH reaction used Tacro VH forward (5Ј- GCGGCCCAGCCGGCCATGGCCGAGGTGGAATT GGTGGAGTCTGGG-3Ј) and Tacro VH reverse (5Ј-CGCCTCCTTCAGGGGCGTCAACTCCTTGGCGG  GACCTGCAGAGACAGTGACCAGAGTCCC-3Ј). VL  reaction used Tacro VL forward (5Ј-AAGGAGTT  GACGCCCCTGAAGGAGGCGAAGGTCTCTGATG  TTTTGATGACCCAAACTCCA-3Ј) and Tacro VL  reverse (5Ј-AGACTCGAGGGCGGCCGCCCGTT  TCAGCTCCAGCTTGGTCCC-3Ј 
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BINDING ANALYSIS OF scFV CLONES
We determined dissociation rates as described (19 ) . Induced cells were first saturated with biotinylated tacrolimus (bt-tacro) antigen at 25°C, washed, and incubated at 25°C with 100-fold molar excess unlabeled tacrolimus (Astellas Pharma, Inc.). Reactions were performed in a selection diluent composed of PBS pH 7.4, 1% BSA, and 10% methanol. Individual samples were withdrawn at various time points and analyzed by flow cytometry to determine the amount of bt-tacro remaining after addition of streptavidin-R-phycoerythrin (SA-PE) (1:200) (Invitrogen). We used a firstorder exponential decay equation (see Supplemental Methods and Materials in the Data Supplement that accompanies the online version of this article at http:// www.clinchem.org/content/vol54/issue6) to fit the antigen-binding mean fluorescence intensity (MFI) obtained from each time point and calculate the dissociation rate constant (k off ).
We determined quantitative equilibrium binding using flow cytometry as described (19, 20 ) . Typically, a titration of bt-tacro concentrations ranging from 10-fold above to 5-fold below the equilibrium constant for each clone were incubated with 10 6 yeast per reaction in the selection diluent containing 10% methanol. Incubation volumes were adjusted to limit antigen depletion (assuming 5 ϫ 10 4 scFv/cell), and the reactions were allowed to equilibrate overnight. Binding of bttacro antigen to the yeast-displayed scFv was detected using SA-PE (diluted 1:200). To calculate the equilibrium affinity constant (K d ), we fitted the MFI of the antigen-binding channel to a nonlinear least-squares regression (see Supplemental Methods and Materials in the online Data Supplement).
MUTAGENIC LIBRARY CONSTRUCTION
Individual libraries, in which 3 successive complementarity determining region (CDR) amino acid positions are mutated, were generated for all 6 CDRs (see Supplemental Methods and Materials in the online Data Supplement). Tacrolimus WT scFv pYD41 plasmid DNA was amplified to introduce a "gap" in each CDR region (primers listed in Supplemental Table 1 in the online Data Supplement). The CDR gap was replaced by a degenerate single-strand oligonucleotide encoding all 20 amino acid possible replacements within the 3-amino acid mutagenic window ( Fig. 2 ) (Midland Certified Reagent Co.) flanked by regions of homology to the amplified vector to facilitate recombination. Approximately 1 g of gapped vector and 16 g of each individual degenerate single-strand oligonucleotide were cotransformed into yeast as outlined previously (21 ) to generate 51 individual libraries spanning every CDR residue of the tacrolimus 1-60-46 antibody. Yeast cells containing reconstituted vector after homologous recombination were propagated in SD-CAA media at 30°C with shaking. We determined transformation efficiency by dilution plating of each library after transformation. Individual libraries within each CDR region were normalized and pooled before selection.
AFFINITY MATURATION SELECTIONS
An overrepresentation (Ն10ϫ) of each mutagenic library or sort output from a previous round of selection, induced for scFv expression, was incubated with 0.1 mol/L bt-tacro and anti-V5 monoclonal antibody (mAb) (2.5 mg/L) (Invitrogen) in the selection diluent (PBS, pH 7.4, 1% BSA, and 10% methanol) at 25°C to saturate surface binding. Cells were washed and incubated at 25°C with 100-fold molar excess of unlabeled tacrolimus for a fixed period (15 ) in the selection diluent [typically 3ϫ-5ϫ the dissociation half-life (t 1/2 )] (see Supplemental Methods and Materials in the online Data Supplement). We detected the amount of bt-tacro antigen remaining on each cell using SA-PE (1: 200 dilution) and normalized binding to the amount of scFv expression using Alexa Fluor 488 goat antimouse (GaM-488, 1:100 dilution; Invitrogen).
Clones with enhanced binding were enriched using FACS on a FACSAria cell sorter (BD Biosciences). Typically the brightest 0.1% to 1.0% of scFv-expressing, antigen-binding cells after dissociation in 10% methanol were sorted. We performed 2 rounds of sorting and regrowth per library to isolate enriched populations of improved mutants. After each round of sorting, we plated an aliquot of cells on SD-CAA agar plates to obtain individual clones for sequence identification and further antigen-binding analysis.
GENERATION OF TACROLIMUS COMBINATORIAL MUTANT
CLONES
Using PCR amplification (see Supplemental Methods and Materials in the online Data Supplement), we constructed combinatorial clones containing various mutations in the H2, L1, and L3 CDR regions. Each clone was amplified with appropriate primers (see Supplemental Table 2 in the online Data Supplement). After amplification of representative portions of each VL mutant containing homology in the framework 3 region, intact VL genes combining the L1 mutation with the L3 mutations were reconstructed and then combined by SOE-PCR using VL gap forward and reverse primers. Intact scFv genes containing the various mutant combinations in both VH and VL domains (see Supplemental Table 3 in the online Data Supplement) were reconstructed by SOE-PCR, using VH gap and VL gap reverse primers. The resulting combinatorial mutant scFv were cloned into the pYD41 vector using homologous recombination after transformation into EBY100 as described (21 ) using 1 g of each amplified combinatorial mutant scFv gene and 0.1 g pYD41 linearized with SfiI and NotI.
IgG EXPRESSION OF TACROLIMUS MUTANT ANTIBODIES
We converted selected tacrolimus mutant scFv clones into murine Ig2a/ antibodies by PCR amplification of the variable domains, followed by ligation into appropriate pBOS vector (22 ) . We amplified mutant VH genes using Tacro VH IgG2a forward (5Ј-TTCTT GTCGCGATTTTAAAAGGTGTCCAGTGCGAGGT GGAATTGGTGGAGTCT-3Ј) and Tacro VH IgG2a reverse (5Ј-TGTTTTAGCGCTTGCAGAGACAGTGA 
Sequence of each WT CDR in the first row. Dashes indicate identity to WT sequence. Unique mutants isolated after selection are shown at top, combinatorial mutant clones at bottom. IgG name denotes clones that were expressed as IgG for assay testing.
CCAGAGT-3Ј). We amplified mutant VL genes using Tacro VL mCk forward (5Ј-CCCGGCTCGCGATGC GATGTTTTGATGACCCAAACT-3Ј) and Tacro VL Ck reverse (5Ј-AGCATCAGCGCTCGCCCGTTTCA GCTCCAGCTT-3Ј). We cotransfected pBOS plasmids into HEK-293 cells and purified the resulting supernatants over protein A column.
AFFINITY DETERMINATION OF TACROLIMUS 1-60-46 MUTANT
IgG ANTIBODIES
We determined the equilibrium dissociation constants for both the Tacrolimus AM 2 IgG and the Tacrolimus WT mAb IgG using kinetic exclusion assay (KinExA ® ) (Sapidyne Instruments) (23 ) . A constant amount of IgG antibody was incubated with various concentrations (10 -8 to 10 -13 mol/L) of tacrolimus drug in the selection diluent (PBS, pH 7.4, 1% BSA, and 10% methanol) and allowed to come to equilibrium before sampling. We determined the K d by analyzing the amount of free binding sites vs the amount of antigen present in the reaction sample and fitting to a 1:1 reversible binding model using KinExA Pro Software (version 1.0.3; Sapidyne Instruments).
TACROLIMUS MUTANT IgG IMMUNOASSAY EVALUATION
The anti-tacrolimus mutant IgGs were individually immobilized to GaM-coated paramagnetic microparticles. The tacrolimus test sample was mixed with Ar- chitect Tacrolimus whole blood precipitation reagent (1L77-55; Abbott Laboratories) and incubated with the microparticles and a tracer reagent (1L77; Abbott Laboratories). The tracer molecule contains tacrolimus attached covalently to acridinium through a linker at position 32. Calibration curves were generated after titration of tacrolimus; data are plotted as ratio of signal for each concentration relative to the 0 g/L control. Each data point is the mean of 3 replicates. LOD was calculated as the lowest tacrolimus concentration distinguishable from zero with 95% confidence, assuming a constant 3% relative light unit (RLU) CV.
Results
AFFINITY MATURATION SELECTIONS
We isolated VH and VL genes from tacrolimus 1-60-46 hybridoma cell line and used them to construct the WT scFv antibody for display on yeast cell surface. The tacrolimus WT scFv has a k off of 9.4 ϫ 10 -4 (Ϯ1.8 ϫ 10 -4 )/s in a selection diluent (composed of PBS, pH 7.4, 1% BSA, and 10% methanol) to mimic tacrolimus whole blood immunoassay conditions. We used a dissociation rate selection strategy to identify tacrolimus variants with improved binding characteristics in the whole blood immunoassay selection diluent. Individual libraries within each CDR region were pooled before selection (e.g., H1 libraries 1-8 were combined to generate the H1 master library); however, each CDR master library was kept separate during the selection process (Fig. 2) . Three libraries (H2, L1, and L3) showed improved binding characteristics over the tacrolimus WT scFv clone after 2 rounds of selection (Fig. 3) .
We sequenced individual clones from each of the 3 libraries with improvements (Table 1) and characterized unique clones ( Table 2 ). The H2 library had 3 unique clones, all of which contained a consensus tyrosine-to-tryptophan change at residue 62 (IMGT numbering (24 )) ( Table 1) . Unexpectedly, 2 of the 3 clones also contained a valine-to-alanine mutation in residue 110 of VL CDR3. Clone H2-1A had the greatest improvement (nearly 6-fold relative to WT), with a k off of 1.6 ϫ 10 -4 /s in the selection diluent. The L1 library also had 3 unique clones, all of which contained a consensus serine-to-glycine change at residue 28 ( Table 1) . The L1 clones also contained the same unexpected valine-to-alanine mutation in residue 110 of VL CDR3. Clone L1-1B had the greatest improvement (nearly 5-fold relative to WT), with a k off of 1.9 ϫ 10 -4 /s in the selection diluent. The L3 library had 6 unique clones in which valine was changed to either cysteine or serine at residue 110 (Table 1 ). The best L3-cysteine mutant (L3-1A) was nearly 8-fold improved relative to WT, with a k off of 1.2 ϫ 10 -4 /s in the selection diluent. The best L3-serine clone (L3-2B) was approximately 3-fold Bivariate plots after dissociation in selection diluent containing 10% methanol of the WT scFv clone and 3 libraries that were enriched for improved binders after second-round selection. scFv expression was detected using anti-V5 mAb/GaM-488 and is indicated with an arrow on the x-axis. Antigen binding was detected using bt-tacro/SA-PE and is indicated with an arrow on the y-axis. The degree of antigen binding after dissociation of the scFv-expressing population for the WT clone is indicated and included in all plots for comparison. The H2, L1, and L3 libraries show an increased level of antigen-binding MFI after 2 rounds of selection denoted by a shift of the population above the "WT" signal gate into the "Improved" signal gate along the y-axis. Individual cells from each of these libraries were isolated and characterized.
better than WT, with a k off of 3.2 ϫ 10 -4 /s in the selection diluent.
ANALYSIS OF TACROLIMUS COMBINATORIAL MUTANT CLONES
We used clones having the greatest improvement in dissociation rate from each master CDR library to construct scFv genes containing different pairings of the individual mutations. Combinatorial clones containing various mutations in the H2 (H2-1A), L1 (L1-1B), and L3 (L3-1A, L3-2B, and L1-1B, which contains V110A mutation) CDR regions were constructed by SOE-PCR. For simplicity, the L3 mutants were labeled as L3 cys, L3 ser, and L3 ala. The names and CDR sequences of the various combinatorial mutants are shown at the bottom of Table 1 .
The dissociation rates and equilibrium dissociation constants for each combinatorial mutant, determined by flow cytometry in the selection diluent, are listed in Table 2 . Many of the combinatorial mutants have additive improvements relative to each single mutant. Combinatorial mutant H2-L3 cys has the slowest k off (5.5 ϫ 10 -5 /s), 17-fold better than the WT clone and Ͼ2-fold better than any single mutant clone. This clone has a K d of 7.4 ϫ 10 -11 mol/L for bt-tacro and is 7.5-fold better than WT. Combinatorial mutant H2-L1-L3 ala has the lowest K d (3.8 ϫ 10 -11 mol/L), which is nearly a 15-fold improvement relative to the WT clone and approximately 4-fold better than any single mutant clone. This clone also had Ͼ12-fold improved dissociation rate (7.5 ϫ 10 -5 /s) relative to WT. Conversely, combining the L1 mutation with either the L3 cys or L3 ser mutations caused a reduction in dissociation rate improvement relative to any of the individual mutant clones and an overall decrease in K d for the L1-L3 cys mutant relative to the WT clone.
FUNCTIONAL TESTING OF TACROLIMUS IgG MUTANTS
Three of the combinatorial mutants were transiently expressed from mammalian cells as murine IgG2a/ antibodies (denoted tacrolimus AM 1-3) to allow direct comparison to the parental monoclonal antibody currently used in the Architect Tacrolimus immunoassay (Table 1) . We determined the solution-based equilibrium affinity of the tacrolimus WT and AM 2 We tested tacrolimus combinatorial mutants AM 1-3 in an automated tacrolimus assay using a competitive format on the Architect instrument. Calibration curves were generated after titration of tacrolimus and data were plotted as the ratio of signal for each concentration to the signal for the 0 g/L sample (X/A ratio). The results from an experiment using a set of calibrator samples ranging from 0 to 30 g/L are shown in Fig.  4A . A tacrolimus concentration of 3 g/L was able to displace 41% of the tracer with the tacrolimus WT IgG. The same 3-g/L sample was able to displace 78%, 79%, and 80% for AM 1-3 IgG, respectively. A second experiment was performed with a new set of calibrators ranging from 0 to 5 g/L; results are shown in Fig. 4B . A tacrolimus concentration of 1 g/L was able to displace only 15% of the tracer with the tacrolimus WT IgG. Conversely, the same 1-g/L sample was able to displace 58%, 35%, and 54% for AM 1-3 IgG. The LOD with this prototype assay using the tacrolimus AM IgG was decreased 3-to 6-fold relative to tacrolimus 1-60-46 WT mAb. Tacrolimus AM 1 has a LOD of 80 g/L, AM 2 has a LOD of 170 g/L, AM 3 has a LOD of 100 g/L, and the WT mAb has a LOD of 470 g/L.
Discussion
We used yeast display to increase the affinity of the tacrolimus 1-60-46 mAb used in a commercial immunoassay to monitor whole blood concentration of the immunosuppressant drug tacrolimus. We used VH and VL genes isolated from the hybridoma cell line to construct a scFv antibody for in vitro directed evolution. Mutagenic libraries, in which every possible amino acid replacement was sampled at each CDR position, were screened for improved binding kinetics in a selection diluent designed to mimic conditions used for drug extraction from whole blood. Several clones with improved binding were isolated, and individual mutations were then combined for greater binding enhancements (Tables 1 and 2 ). Selected scFv clones were converted to full-length IgG and demonstrated significant improvement in the Architect Tacrolimus competitive immunoassay (Fig. 4) . As expected, the binding improvements were maintained as the mutant scFv constructs were converted to IgG. This conservation validates the conversion of murine mAb to the scFv format instead of the heterodimeric Fab. Crossreactivity with tacrolimus metabolites was not tested because complete validation of the derived antibodies is beyond the scope of this work; however, we do not anticipate that the specificity will be altered.
Sequence analysis of the selected mutants shows that only 3 residues, each in a different CDR, are likely responsible for improved dissociation kinetics ( Table 1) . VH CDR 2 contained a consensus tyrosineto-tryptophan change at residue 62. VL CDR 1 contained a consensus serine-to-glycine change at residue 28. The valine at residue 110 in VL CDR 3 was changed to alanine, cysteine, or serine. The unique clones from each library contain different sequences that flank each of these 3 critical residues. The heterogeneity of the flanking sequences is likely due to the 3-residue window used to construct the mutagenic libraries (e.g., AWT for H2-1A, KWV for H2-1B, and EWT for H2-3B) ( Table 1 ). However, the local environment of each unique mutation window may have slightly different effects on the overall canonical conformation of the CDR loop and may affect binding (25 ) . The unexpected V110A mutation in VL CDR 3 of the H2 and L1 clones occurred at the same position that was changed in all of the mutants from the L3 library and was likely introduced by PCR during library construction. This congruence further indicates that valine is not well tolerated in this position for this antigen system. Although the single V110A change alone does provide some improved binding relative to the parental clone, this change is not solely responsible for the improved dissociation observed in any of the H2 or L1 mutant clones (data not shown). Many of the combinatorial mutations appeared to be additive; however, combining the S28G mutation in VL CDR 1 with either V110C or V110S mutation in VL CDR 3 negates much of the benefit of any of the clones alone, and overall affinity is equivalent to the WT clone. It is tempting to speculate, but the mechanisms by which any of the single or combinatorial mutations affect antigen binding are difficult to infer without comparing cocrystallographic structures.
Many examples have been published of in vitro directed evolution to improve antibody affinity or specificity (10 -12, 14, 26 -30 ) . These reports have largely centered on improved efficacy of therapeutic agents, mechanistic understanding of the bimolecular interaction under study, or technology development. The degree of affinity improvement obtained with the work presented here is in keeping with previous results obtained with both yeast and other in vitro antibody display systems. Affinity improvements Ͼ1000-fold have been reported (10, 30 ) ; however, in contrast to the work presented here, those results were obtained after multiple rounds of mutagenesis and screening from parental clones with much lower starting affinities (typically low nmol/L) than that of the tacrolimus 1-60-46 antibody. mAb clones have usually undergone extensive somatic hypermutation during the immunization process unlike clones derived from in vitro antibody discovery efforts. Nevertheless, this iterative in vitro approach is readily applicable to our work if warranted, and its use will ultimately depend on both the starting affinity and desired level of detection.
Although it is generally accepted that improved recognition elements are prerequisites for the development of highly sensitive diagnostic assays, to our knowledge, this is the first example to show enhanced performance with a commercially available immunoassay. The improved LOD of each of the tacrolimus 1-60-46 AM IgGs will allow more robust and sensitivity assays to be developed as more efficacious treatment regimens are adopted. This approach is also easily adaptable to most antibody-antigen systems and provides the ability to improve a wide range of immunoassays.
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